We considered longitudinal changes of POSTN in IPF patients and found that its increase predicts clinical progression better than other biomarkers considered, outperforming a panel of alternative biomarkers selected from literature review. The gene discussed is POSTN; the disease is idiopathic pulmonary fibrosis.